These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 11329956)

  • 1. [Clinical outcome and analysis of radical prostatectomy in clinical stage B and C prostate cancer].
    Miyoshi Y; Uemura H; Mikata K; Ohuchi H; Jinza S; Yao M; Takeda M; Masuda M; Noguchi S; Noguchi K; Kubota Y; Hosaka M
    Hinyokika Kiyo; 2001 Mar; 47(3):163-8. PubMed ID: 11329956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
    Ramos CG; Roehl KA; Antenor JA; Humphrey PA; Catalona WJ
    J Urol; 2004 Jul; 172(1):137-40. PubMed ID: 15201754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy.
    Shekarriz B; Upadhyay J; Bianco FJ; Tefilli MV; Tiguert R; Gheiler EL; Grignon DJ; Pontes JE; Wood DP
    Prostate; 2001 Aug; 48(3):136-43. PubMed ID: 11494329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment results of radical prostatectomy in clinical stage B and C prostate cancer: comparison of the neoadjuvant therapy group versus the surgery group; retrospective analysis of 80 cases].
    Ogura Y; Sakata Y; Wakita T; Hayashi N; Hioki T; Sugimura Y
    Hinyokika Kiyo; 2003 Sep; 49(9):515-20. PubMed ID: 14598688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
    Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
    Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ; Partin AW; Epstein JI; Walsh PC
    Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
    Antenor JA; Roehl KA; Eggener SE; Kundu SD; Han M; Catalona WJ
    Urology; 2005 Jul; 66(1):156-60. PubMed ID: 15992903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.